JP2004507559A5 - - Google Patents

Download PDF

Info

Publication number
JP2004507559A5
JP2004507559A5 JP2002523958A JP2002523958A JP2004507559A5 JP 2004507559 A5 JP2004507559 A5 JP 2004507559A5 JP 2002523958 A JP2002523958 A JP 2002523958A JP 2002523958 A JP2002523958 A JP 2002523958A JP 2004507559 A5 JP2004507559 A5 JP 2004507559A5
Authority
JP
Japan
Prior art keywords
composition
antibody
atcc accession
number pta
accession number
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002523958A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004507559A (ja
Filing date
Publication date
Priority claimed from US09/940,101 external-priority patent/US20020119148A1/en
Application filed filed Critical
Publication of JP2004507559A publication Critical patent/JP2004507559A/ja
Publication of JP2004507559A5 publication Critical patent/JP2004507559A5/ja
Pending legal-status Critical Current

Links

JP2002523958A 2000-09-01 2001-08-29 ＥｒｂＢ４アンタゴニスト Pending JP2004507559A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22967900P 2000-09-01 2000-09-01
US26551601P 2001-01-31 2001-01-31
US09/940,101 US20020119148A1 (en) 2000-09-01 2001-08-27 ErbB4 antagonists
PCT/US2001/026984 WO2002018444A2 (en) 2000-09-01 2001-08-29 Erbb4 antagonists

Publications (2)

Publication Number Publication Date
JP2004507559A JP2004507559A (ja) 2004-03-11
JP2004507559A5 true JP2004507559A5 (https=) 2008-10-09

Family

ID=27397993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002523958A Pending JP2004507559A (ja) 2000-09-01 2001-08-29 ＥｒｂＢ４アンタゴニスト

Country Status (11)

Country Link
US (6) US20020119148A1 (https=)
EP (1) EP1351744B1 (https=)
JP (1) JP2004507559A (https=)
AT (1) ATE374642T1 (https=)
AU (2) AU2001286918B2 (https=)
CA (1) CA2420062C (https=)
DE (1) DE60130797T2 (https=)
DK (1) DK1351744T3 (https=)
ES (1) ES2295202T3 (https=)
IL (2) IL154495A0 (https=)
WO (1) WO2002018444A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
JP5052736B2 (ja) * 2001-05-30 2012-10-17 中外製薬株式会社 タンパク質製剤
AU2003237367A1 (en) * 2002-06-03 2003-12-19 Chiron Corporation Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
ES2392525T3 (es) 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
TWI229650B (en) * 2002-11-19 2005-03-21 Sharp Kk Substrate accommodating tray
JP4527388B2 (ja) * 2003-12-11 2010-08-18 東洋鋼鈑株式会社 ポリペプチドとレセプターとの相互作用を検出する方法、該検出する方法を用いてリガンドまたはリガンド変異体をスクリーニングする方法および該検出する方法を用いる診断方法
KR20120064120A (ko) 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CN101495503A (zh) * 2005-03-07 2009-07-29 塔盖替德分子诊断有限公司 酪氨酸激酶抑制剂组合物及其制造方法和在疾病治疗中的应用
SG178789A1 (en) * 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
WO2009121004A2 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
UA104868C2 (uk) * 2008-08-15 2014-03-25 Меррімак Фармасьютікалз, Інк. Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції
CN102725310A (zh) 2008-11-25 2012-10-10 健泰科生物技术公司 同等型特异性抗her4抗体
CN104447995A (zh) * 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
EP2507381A4 (en) 2009-12-04 2016-07-20 Hoffmann La Roche MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
SI2501817T2 (sl) 2010-02-08 2021-09-30 Regeneron Pharmaceuticals, Inc. Miš z navadno lahko verigo
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
WO2011107100A1 (en) 2010-03-03 2011-09-09 Aarhus Universitet Methods and compositions for regulation of herv4
CA2792327C (en) 2010-03-11 2019-09-24 Merrimack Pharmaceuticals, Inc. Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
EP2640831A1 (en) 2010-11-17 2013-09-25 Sea Lane Biotechnologies,llc. Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
RS59728B1 (sr) 2011-08-05 2020-02-28 Regeneron Pharma Humanizovani miševi univerzalnog lakog lanca
EP2748197A2 (en) 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
MX2015005757A (es) 2012-11-08 2015-11-18 Hoffmann La Roche Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3.
US9725511B2 (en) * 2012-11-08 2017-08-08 Hoffmann-La Roche Inc. Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4
TW201444872A (zh) 2013-03-06 2014-12-01 Merrimack Pharmaceuticals Inc 抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
KR102276752B1 (ko) 2014-03-21 2021-07-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
FR3020063A1 (fr) * 2014-04-16 2015-10-23 Gamamabs Pharma Anticorps humain anti-her4
MX2016014416A (es) 2014-05-14 2017-02-23 Hoffmann La Roche Anticuerpos anti-her3 que se unen a la horquilla beta de her3.
EP3271403A1 (en) 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
US12577324B2 (en) * 2019-12-09 2026-03-17 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity to HER4 and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CA2037440A1 (en) 1990-03-02 1991-09-03 Gregory D. Plowman Her3: a novel egf receptor homolog
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5770567A (en) * 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
HUT76853A (en) 1994-11-14 1997-12-29 Warner Lambert Co 6-aryl pyrido[2,3-d]pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation and pharmaceutical compositions containing the same
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
CA2257839C (en) * 1996-07-12 2012-10-23 Genentech, Inc. Gamma-heregulin
WO1998002540A1 (en) * 1996-07-12 1998-01-22 Genentech, Inc. Chimeric heteromultimer adhesins
EP0950067B1 (en) * 1996-11-27 2007-08-29 Genentech, Inc. Affinity purification of polypeptide on protein a matrix
US6121415A (en) 1997-07-09 2000-09-19 Genentech, Inc. ErbB4 receptor-specific neuregolin related ligands and uses therefor
US6994856B1 (en) * 1997-07-24 2006-02-07 Genentech, Inc. ErbB4 receptor-specific neuregulin related ligands and uses therefor
AU9805398A (en) 1997-10-15 1999-05-03 Children's Medical Center Corporation Novel human egf receptors and use thereof
WO2000031048A1 (en) * 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
CA2412377A1 (en) * 2000-06-06 2001-12-13 Bristol-Myers Squibb Company B7-related nucleic acids and polypeptides and their uses for immunomodulation
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists

Similar Documents

Publication Publication Date Title
JP2004507559A5 (https=)
CN102209730B (zh) 抗cxcr4抗体及其用于治疗癌症的用途
RU2640252C2 (ru) Антитела против фактора роста нервов и способы их получения и применения
CN109952317A (zh) 使用pd-1结合蛋白治疗免疫病症的方法
CN112867507A (zh) 新型抗sirpa抗体
JP2012515746A (ja) 抗ｃｄ１６０モノクローナル抗体及びその使用
MXPA06010929A (es) Anticuerpos anti-miostatina.
CN109689687A (zh) 抗met抗体及其应用
CN116041513B (zh) 靶向rankl的治疗性抗体
CN116867900A (zh) 新型抗pad4抗体
AU2022419233A1 (en) Treatment paradigm for an anti-cd19 antibody therapy
KR20260013489A (ko) TrkA 항체 및 이의 용도
TW202221025A (zh) 用於治療和預防ｃｏｖｉｄ—１９的ｓａｒｓ—ｃｏｖ—２抗體
CA3158491A1 (en) Novel anti-nogo-a antibodies
JPWO2020180819A5 (https=)
US20230391863A1 (en) Bifunctional antagonists of activin and tumor necrosis factor alpha and uses thereof
CN118063609A (zh) 抗cd39抗体及其应用
US20230391892A1 (en) Bifunctional antagonists of tumor necrosis factor alpha and transforming growth factor beta and uses thereof
WO2025103260A1 (zh) Gdf15中和抗体及其用途
CN116284394A (zh) 分离的抗原结合蛋白及其应用
CN121925273A (zh) 由脊髄或脑的障碍引起的疾病所相伴的伴随症状的预防或治疗剂
HK40086174A (zh) 分离的抗原结合蛋白及其应用
CN117980342A (zh) 抗her2抗体及其使用方法
CN120239709A (zh) 抗体、其抗原结合片段及其药物用途
EA052689B1 (ru) Новые антитела к nogo-a